ASCO) published key phase II clinical data on the use of erlotinib as a single-agent therapy for advanced bile duct cancer in 2026.

Wisdom Financial News App News, Sino Biopharmaceutical Limited -B (02617.HK) announced that the company presented the latest research results of its core product, toripalimab monotherapy, for the treatment of Chinese advanced biliary tract cancer patients previously treated with FGFR inhibitors at the 2026 American Society of Clinical Oncology (ASCO) held in Chicago in the form of a poster.